These sessions are not part of the official ASE 2025 Scientific Sessions as planned by the Program Committee or in any way endorsed by or affiliated with ASE.
Friday, September 5
1:30– 2:30 PM
THEATER 2
Seeing the Signs: Mastering the Echo-Based Diagnosis of Obstructive Hypertrophic Cardiomyopathy (oHCM)
Through case studies and interactive demonstrations, attendees will gain valuable insights into the applied techniques of obstructive hypertrophic cardiomyopathy (oHCM) diagnosis and education. This informative session aims to provide a comprehensive overview of the various diagnostic tools specifically used to identify oHCM. Additionally, the faculty will emphasize essential techniques for interpreting diagnostic images, supporting sonographers and healthcare providers with skills to effectively recognize the clues for oHCM.
Objectives
- Demonstrate different diagnostic tools and techniques, including Valsalva, used to identify oHCM through detailed case studies
- Recognize clinical clues that may indicate the need for further assessment of oHCM, in conjunction with recommendations by a healthcare provider
- Provide comprehensive information on specific imaging options and interpreting diagnostic images for effectively diagnosing oHCM
Speakers
Jolyn Becerra, BAS, ACS, RDCS, FASE, Manager, Non-Invasive Cardiology, UT Southwestern Medical Center
Ashlee Davis, ACS, RDCS, RCCS, BSMI, FASE, Chief Technologist, Cardiac Diagnostic Unit, Duke University Hospital
Presented by Cytokinetics
Saturday, September 6
12:30 – 1:30 PM
THEATER 1
Enhancing Cardiac Imaging: The Role of a UEA in Cardiomyopathy Assessment
This symposium explores the pivotal role of ultrasound enhancing agents (UEAs) in echocardiographic assessment of cardiomyopathies. By enhancing image clarity, a UEA facilitates more accurate evaluations of left ventricle endocardial borders, which is crucial in diagnosing and managing cardiomyopathies.
Speaker: Kristen Billick, ACS, RCS, RDCS, FASE
Presented by Lantheus
12:30– 1:30 PM
THEATER 2
AI that Works: Validated Efficiency in Cardiac Ultrasound
Join us for lunch to hear the results of the ASE AI Validation Study, a randomized study that validated AI-based functions in cardiac ultrasound. Discover how AI-powered tools on the ACUSON Origin ultrasound system significantly reduced exam time and ergonomic movement while delivering consistent, reliable measurements with minimal need for manual edits.
ASE AI Validation Study overview: Lissa Sugeng, MD, MPH, FASE
Key takeaways from the study: Neil J. Weissman, MD, FASE
Why AI matters in the echo lab: Steven Walling, ACS, FASE
AI in strain imaging with and without CEU: Jeffrey Hill, ACS, FASE
Presented by Siemens Healthineers
3:45– 4:45 PM
THEATER 1
The Impact of CAMZYOS (mavacamten) on Cardiac Structure and Function
In depth review of the natural history and prognostic markers of HCM and discuss the impact of cardiac myosin inhibition on cardiac structure and function outcomes in adult patients with symptomatic NYHA Class II-III obstructive HCM from pivotal trial and long-term extension data.
Speaker: Dermot M. Phelan, MD, PhD, FASE
Presented by Bristol Myers Squibb
Sunday, September 7
12:30– 1:30 PM
THEATER 1
Pioneering Advancements in Echo Imaging
Join leading experts for a panel discussion around the latest breakthrough in echocardiography. Hear how the latest ultrasound technology will deliver clearer, more reliable insights that empower better clinical decisions.
Speakers
Dr. Pei-Ni Jone, Lurie Children’s Hospital
Dr. Rebecca Perry, UniSA Allied Health & Human Performance
Amy Dillenbeck, Cleveland Clinic
Dr. Luigi Badano, University of Milano Bicocca
Rhonda Hudson, GE HealthCare, Cardiovascular Ultrasound Global Clinical Director
Presented by GE HealthCare
12:30 – 1:30 PM
THEATER 2
Real-World AI for HFpEF & Amyloidosis: Unlocking Diagnostic Power from a Single Echo View
Discover groundbreaking clinical data on the use of AI to advance the detection of HFpEF and Cardiac Amyloidosis. Hear expert insights from Mayo Clinic, The University of Chicago Medicine, and City of Hope. This session shares real-world case studies, customer implementations, and results from the 2025 landmark trial of the first FDA-cleared AI echo-based screening tool for Cardiac Amyloidosis.
Ross Upton, PhD, Founder, CEO & Chief Scientific Officer, Ultromics
Co-Chair, HeartShare AI Committee, NIH
Patricia A. Pellikka, MD, FASE, President, Mayo Clinic Officers and Councilors
Betty Knight Scripps Professor of Cardiovascular Diseases
Editor-in-Chief, JASE
Jeremy A. Slivnick, MD, FASE
Assistant Professor, The University of Chicago Medicine
Faizi A. Jamal, MD, FACC
Chief, Division of Cardiology; Director, Non-Invasive Cardiology Laboratory; Associate Clinical Professor, Department of Medicine, City of Hope
Presented by Ultromics
